Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2015 1
2016 1
2017 3
2018 3
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean sara charmaz (1 results)?
Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer.
Browne AL, Charmsaz S, Varešlija D, Fagan A, Cosgrove N, Cocchiglia S, Purcell S, Ward E, Bane F, Hudson L, Hill AD, Carroll JS, Redmond AM, Young LS. Browne AL, et al. Among authors: charmsaz s. Oncogene. 2018 Apr;37(15):2008-2021. doi: 10.1038/s41388-017-0042-x. Epub 2018 Jan 25. Oncogene. 2018. PMID: 29367763 Free PMC article.
Eph receptors as oncotargets.
Charmsaz S, Boyd AW. Charmsaz S, et al. Oncotarget. 2017 Sep 19;8(47):81727-81728. doi: 10.18632/oncotarget.21045. eCollection 2017 Oct 10. Oncotarget. 2017. PMID: 29137214 Free PMC article. No abstract available.
Innovative Technologies Changing Cancer Treatment.
Charmsaz S, Prencipe M, Kiely M, Pidgeon GP, Collins DM. Charmsaz S, et al. Cancers (Basel). 2018 Jun 19;10(6):208. doi: 10.3390/cancers10060208. Cancers (Basel). 2018. PMID: 29921753 Free PMC article.
Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer.
Ward E, Varešlija D, Charmsaz S, Fagan A, Browne AL, Cosgrove N, Cocchiglia S, Purcell SP, Hudson L, Das S, O'Connor D, O'Halloran PJ, Sims AH, Hill AD, Young LS. Ward E, et al. Among authors: charmsaz s. Clin Cancer Res. 2018 Aug 1;24(15):3692-3703. doi: 10.1158/1078-0432.CCR-17-2615. Epub 2018 Mar 22. Clin Cancer Res. 2018. PMID: 29567811 Free article.
Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference.
Charmsaz S, Collins DM, Perry AS, Prencipe M. Charmsaz S, et al. Cancers (Basel). 2019 Aug 7;11(8):1125. doi: 10.3390/cancers11081125. Cancers (Basel). 2019. PMID: 31394729 Free PMC article.
S100β as a serum marker in endocrine resistant breast cancer.
Charmsaz S, Hughes É, Bane FT, Tibbitts P, McIlroy M, Byrne C, Cocchiglia S, McBryan J, Hennessy BT, Dwyer RM, Kerin MJ, Hill AD, Young LS. Charmsaz S, et al. BMC Med. 2017 Apr 12;15(1):79. doi: 10.1186/s12916-017-0836-2. BMC Med. 2017. PMID: 28399921 Free PMC article. Clinical Trial.
Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma.
Stringer BW, Bunt J, Day BW, Barry G, Jamieson PR, Ensbey KS, Bruce ZC, Goasdoué K, Vidal H, Charmsaz S, Smith FM, Cooper LT, Piper M, Boyd AW, Richards LJ. Stringer BW, et al. Among authors: charmsaz s. Oncotarget. 2016 May 17;7(20):29306-20. doi: 10.18632/oncotarget.8720. Oncotarget. 2016. PMID: 27083054 Free PMC article.
EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.
Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C, Charmsaz S, Cooper LT, Ellacott JK, Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G, Khanna KK, Reynolds BA, Lickliter JD, Boyd AW. Day BW, et al. Among authors: charmsaz s. Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007. Cancer Cell. 2013. PMID: 23410976 Free article.
EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.
Charmsaz S, Beckett K, Smith FM, Bruedigam C, Moore AS, Al-Ejeh F, Lane SW, Boyd AW. Charmsaz S, et al. PLoS One. 2015 Jun 17;10(6):e0130692. doi: 10.1371/journal.pone.0130692. eCollection 2015. PLoS One. 2015. PMID: 26083390 Free PMC article.
11 results
Jump to page